Trial Profile
An open-label study to evaluate safety and efficacy of 750 mg intravenous mepolizumab in subjects with steroid refractory eosinophilic cystitis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Mar 2021
Price :
$35
*
At a glance
- Drugs Mepolizumab (Primary)
- Indications Cystitis
- Focus Therapeutic Use
- Acronyms MEPOCYS
- 01 Mar 2021 Status changed from recruiting to completed.
- 16 Sep 2014 New trial record